支气管热成形术治疗重症哮喘的长期结局:两项前瞻性多中心研究3年随访比较
本文比较PAS2研究前190例与AIR2试验190例支气管热成形术受试者3年随访结局。PAS2受试者更年长、更肥胖、吸入激素剂量更高且基线重度急性发作和住院比例更高;术后3年PAS2重度急性发作、急诊就诊和住院分别显著减少45%、55%和40%,与AIR2结果一致,提示哮喘控制较差人群中同样获益。
要点
- PAS2受试者较AIR2更年长、更肥胖且吸入激素剂量更高,基线重度急性发作和住院比例更高。
- 术后3年PAS2重度急性发作、急诊就诊和住院分别显著减少45%、55%和40%。
- 尽管PAS2人群哮喘控制可能更差,支气管热成形术后的改善与AIR2试验相似。
核心结论
- PAS2研究显示支气管热成形术后哮喘控制改善与AIR2试验相似,尽管入组人群可能哮喘控制更差。
研究设计与样本
- 比较PAS2研究前190例支气管热成形术受试者与AIR2试验190例支气管热成形术受试者的3年随访结局。
- PAS2为正在进行的上市后研究,共279例受试者接受支气管热成形术。
主要发现
- PAS2受试者平均年龄45.9岁、平均体重指数32.5 kg·m-2、平均吸入激素剂量2301 μg·day-1,均高于AIR2的40.7岁、29.3 kg·m-2和1961 μg·day-1。
- 支气管热成形术前12个月内,PAS2有74%受试者发生重度急性发作、15.3%住院,高于AIR2的52%和4.2%。
- 术后3年,PAS2重度急性发作、急诊就诊和住院分别显著减少45%、55%和40%。
临床怎么用
- 在哮喘控制可能较差的重症哮喘患者中,支气管热成形术仍可带来重度急性发作、急诊就诊和住院的显著减少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Bronchial thermoplasty is an endoscopic therapy for severe asthma. The previously reported, randomised sham-controlled AIR2 (Asthma Intervention Research 2) trial showed a significant reduction in severe asthma exacerbations, emergency department visits and hospitalisations after bronchial thermoplasty. More "real-world" clinical outcome data is needed.This article compares outcomes in bronchial thermoplasty subjects with 3 years of follow-up from the ongoing, post-market PAS2 (Post-FDA Approval Clinical Trial Evaluating Bronchial Thermoplasty in Severe Persistent Asthma) study with those from the AIR2 trial.279 subjects were treated with bronchial thermoplasty in the PAS2 study. We compared the first 190 PAS2 subjects with the 190 bronchial thermoplasty-treated subjects in the AIR2 trial at 3 years of follow-up. The PAS2 subjects were older (mean age 45.9 versus 40.7 years) and more obese (mean body mass index 32.5 versus 29.3 kg·m-2) and took higher doses of inhaled corticosteroids (mean dose 2301 versus 1961 μg·day-1). More PAS2 subjects had experienced severe exacerbations (74% versus 52%) and hospitalisations (15.3% versus 4.2%) in the 12 months prior to bronchial thermoplasty. At year 3 after bronchial thermoplasty, the percentage of PAS2 subjects with severe exacerbations, emergency department visits and hospitalisations significantly decreased by 45%, 55% and 40%, respectively, echoing the AIR2 results.The PAS2 study demonstrates similar improvements in asthma control after bronchial thermoplasty compared with the AIR2 trial despite enrolling subjects who may have had poorer asthma control.
引用
- Chupp G, Laviolette M, Cohn L, et al. Long-term outcomes of bronchial thermoplasty in subjects with severe asthma: a comparison of 3-year follow-up results from two prospective multicentre studies. Eur Respir J. 2017. PMID: 28860266. doi:10.1183/13993003.00017-2017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。